The adjuvant GLA-AF enhances human intradermal vaccine responses

por Carter, Darrick, van Hoeven, Neal, Baldwin, Susan, Levin, Yotam, Kochba, Efrat, Magill, Al, Charland, Nathalie, Landry, Nathalie, Nu, Khin, Frevol, Aude, Ashman, Jill, Sagawa, Zachary K., Beckmann, Anna Marie, Reed, Steven G.
Publicado 2018

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

por Coler, Rhea N., Day, Tracey A., Ellis, Ruth, Piazza, Franco M., Beckmann, Anna Marie, Vergara, Julie, Rolf, Tom, Lu, Lenette, Alter, Galit, Hokey, David, Jayashankar, Lakshmi, Walker, Robert, Snowden, Margaret Ann, Evans, Tom, Ginsberg, Ann, Reed, Steven G.
Publicado 2018

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults

por Sagawa, Zachary K., Goman, Cristina, Frevol, Aude, Blazevic, Azra, Tennant, Janice, Fisher, Bridget, Day, Tracey, Jackson, Stephen, Lemiale, Franck, Toussaint, Leon, Kalisz, Irene, Jiang, Joe, Ondrejcek, Lisa, Mohamath, Raodoh, Vergara, Julie, Lew, Alan, Beckmann, Anna Marie, Casper, Corey, Hoft, Daniel F., Fox, Christopher B.
Publicado 2023

Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial

por Vanni, Tazio, Thomé, Beatriz C., Sparrow, Erin, Friede, Martin, Fox, Christopher B., Beckmann, Anna Marie, Huynh, Chuong, Mondini, Gabriella, Silveira, Daniela H., Viscondi, Juliana Y. K., Braga, Patrícia Emilia, da Silva, Anderson, Salomão, Maria da Graça, Piorelli, Roberta O., Santos, Joane P., Gattás, Vera Lúcia, Lucchesi, Maria Beatriz B., de Oliveira, Mayra M. M., Koike, Marcelo E., Kallas, Esper G., Campos, Lucia M. A., Coelho, Eduardo B., Siqueira, Marilda A. M., Garcia, Cristiana C., Miranda, Milene Dias, Paiva, Terezinha M., Timenetsky, Maria do Carmo S. T., Adami, Eduardo A., Akamatsu, Milena A., Ho, Paulo Lee, Precioso, Alexander R.
Publicado 2022